Genocea Biosciences Secures $30,000,000 Series C Financing
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=120b514e-6cfe-4e38-a16d-ee2f1c16c51b&Preview=1 - Date
10/10/2012 - Company Name
Genocea Biosciences - Mailing Address
161 First Street Cambridge, MA 02142 - Company Description
Genocea is developing a new class of human vaccines based on a revolutionary platform for the rapid discovery of antigens that induce T cell immunity. The platform, which dramatically reduces the time to discover vaccine candidates, uniquely employs a proprietary, high-throughput approach that mimics the natural immune response in the laboratory to comprehensively screen for antigens that are protective across diverse human populations. - Website
http://www.genocea.com - Transaction Type
Venture Equity - Transaction Amount
$30,000,000 - Transaction Round
Series C - Proceeds Purposes
The developer has been ramping up a Phase I/IIa study of its lead program–GEN-003–for herpes simplex virus-2. - M&A Terms
- Venture Investor
Bill & Melinda Gates Foundation - Venture Investor
Johnson & Johnson Development Corporation - Venture Investor
Skyline Ventures - Venture Investor
Polaris Venture Partners - Venture Investor
SR One - Venture Investor
Lux Capital - Venture Investor
Cycad Group - Venture Investor
Auriga Partners - Venture Investor
Morningside Group
